title: iRECIST Guideline Unveiled for Immunotherapies.
abstract: The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kinds of drugs.
mesh_terms: D006801:Humans; D007167:Immunotherapy; D066066:Response Evaluation Criteria in Solid Tumors